The latest featured news from Pituitary World News
Today’s program focuses on interactions between the medical and psychological worlds. Join Dr. Blevins and me as we welcome PWN contributor, marriage and family therapist, and author Linda Rio for a fascinating discussion on how pituitary disease, or any chronic disease, manifests itself mentally and emotionally. Listen as we muse on how emotional health and psychological distress can affect people’s daily lives and how they deal with their disorders.
After a few virtual meetings these past years, I was back at UC Berkeley/UCSF’s joint medical program for an in-person gathering with some of the brightest and most engaged medical students on the planet. This is, without a doubt, one of my favorite things to do since founding PWN, and I look forward to it every year.
This week’s Live-talk offers critical knowledge that people affected with pituitary and endocrine diseases need to know to ensure they receive proper treatment. Dr. Sylvia Asa, a pioneer in endocrine and pituitary tumor pathology, talks with Dr. Lewis Blevins about her work in the field and the reclassification of pituitary adenomas to Pituitary Neuroendocrine Tumors, or PitNets.
It seemed to Linda neither the medical nor mental health professions could adequately identify and treat these disorders, and a more holistic, comprehensive approach needed to be taken.
Our briefing today covers articles on costs and access to therapies, sugar and artificial sweeteners, surprising news on where we are finding endocrine disruptive chemicals, an amazing discovery about a new brain layer, and a bunch of information on Cannabidiol (CBD) focusing on what we know and what we don’t. This is great info you don’t want to miss. Read on!
Pituitary World News has undertaken an initiative to understand and share the complicated issues related to medication access so patients can join us in advocating for a better system. Don’t miss this engaging podcast.
Well, it looks like Diabetes Insipidus is on the way out, at least from the naming point of view. After the work done in Basel (Universitätsspital Basel), recently published in The Lancet, an international consensus group proposed a name change from Diabetes Insipidus to Arginine Vasopressin Deficiency or AVP-D, or Arginine Vasopressin Resistance or AVP-R, depending on the type.
Here are links to Dr. Blevins’ discussion of five drugs to treat hypercortisolism.